The DLL3 drug ... cancer and breast cancer. After CEO Bruce Cozadd highlighted the company’s continued interest in dealmaking, Jazz agreed to buy Chimerix for $935 million to get hold of ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year ... Itovebi (inavolisib) has an FDA green light as part of a combination ...

New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

Instead, he predicted, blood tests will allow doctors to squelch drug-resistant cancers before the tumors have a chance to grow. The new study involved 315 patients with advanced breast cancer ...

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

3 Summer "Power Patterns" Are About to Trigger (One With 90% Win Rate) - Get The Details Now Roche ... Also Read: Ten-Year Data From Roche’s Breast Cancer Trial Shows Perjeta-Based Regimen ...

Beatriz Sawaya came to MSK from Brazil to receive a new treatment for resistant breast cancer as ... respond to this drug,” she says. “It’s a phenomenal story.” Back to top The clinical trials were ...

The investigational oral agent vepdegestrant more than doubled median progression-free survival (PFS) versus fulvestrant ...

Rep Kim Schrier, MD, (D-Wash.), said on X yesterday that some of the newly appointed ACIP replacements are anti-vaccine ...

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...